Description
Retatrutide peptide (GLP-3) is an investigational triple hormone receptor agonist widely studied for its potential role in metabolic health, weight management, and glucose regulation. Unlike traditional incretin therapies, Retatrutide is designed to simultaneously activate GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors, making it one of the most advanced compounds in GLP-1 research. Retatrutide research continues to investigate how this triple-agonist mechanism may influence energy expenditure, appetite regulation, and overall metabolic function.
Current Retatrutide peptide research has explored its interaction with multiple metabolic pathways involved in insulin secretion, glucagon signaling, satiety, gastric emptying, and lipid metabolism. Numerous Retatrutide studies have examined its potential effects on body weight regulation, energy balance, glucose homeostasis, and metabolic physiology through its unique multi-receptor activity. Researchers continue to evaluate Retatrutide (GLP-3) to better understand its pharmacological profile, receptor selectivity, and biological mechanisms in laboratory models focused on obesity, type 2 diabetes, and metabolic disorders.
As interest in next-generation incretin therapies continues to expand, Retatrutide peptide remains an important investigational compound across multiple areas of metabolic and endocrine research. Ongoing preclinical and clinical studies continue to improve the scientific understanding of Retatrutide, its triple-agonist mechanism, and its potential applications in obesity research, metabolic science, and hormone regulation.
Retatrutide (GLP-3) is intended for laboratory and scientific research purposes only. This investigational research peptide is not approved for human consumption or therapeutic use.








Joseph G. –
Appreciated the attention to detail and secure packaging. Used for glp-1 research applications.